



# Takeda Information

## (Correction) FY2013 Full Year Results “Data Book”

This is for filing a correction of the FY2013 full year results “Data Book”, which was published on May 8, 2014, as part of the supplementary materials for the financial statements for the same period.

### 1. Correction: FY2013 full year results “Data Book”, page 19 (incorrect section highlighted)

<incorrect>

<b>SYR-472</b> <trelagliptin>	DPP-4 inhibitor (oral)	Diabetes mellitus	Jpn US EU	Filed (Mar 14) P-II P-II	In-house
----------------------------------	---------------------------	-------------------	-----------------	--------------------------------	----------

<correct>

<b>SYR-472</b> <trelagliptin>	DPP-4 inhibitor (oral)	Diabetes mellitus	Jpn	Filed (Mar 14)	In-house
----------------------------------	---------------------------	-------------------	-----	----------------	----------

### 2. Addition: FY2013 full year results “Data Book”, page 23 (added section highlighted)

<correct>

#### **Discontinued projects** Discontinued since release of FY2012 results (May 9<sup>th</sup>, 2013)

Development code/ product name <generic name>	Indications (Stage)	Reason
<b>AMG 479</b> <ganitumab>	Metastatic pancreas cancer (Jpn P-III)	Independent Data Monitoring Committee (DMC) reviewed the interim analysis and concluded that it was unlikely to meet the primary endpoint
<b>TAK-491</b> <azilsartan medoxomil>	Hypertension (fixed-dose combination with chlorthalidone) (EU P-III)	Discontinued due to a reassessment of the marketing opportunity in the EU
<b>TAK-428</b> <->	Diabetic neuropathy (US/EU P-II)	Discontinued based on reassessment of portfolio prioritization
<b>TAK-390MR</b> <dexlansoprazole>	Erosive esophagitis (healing and maintenance), Non-erosive gastro-esophageal reflux disease (Jpn P-II)	Discontinued due to advanced progress of TAK-438 program in Japan
<b>TAK-329</b> <->	Diabetes (P-I)	Discontinued due to the clinical data failing to meet the criteria for stage-up
<b>TAK-875</b> <fasiglifam>	Diabetes (P-III)	Discontinued due to concerns about liver safety
<b>SYR-472</b> <trelagliptin>	Diabetes (US, EU P-II)	Discontinued in the US and EU after consideration of the development costs that would be necessary in order to obtain approval

Discontinued projects since the announcement of FY2013 3Q results (February 5<sup>th</sup>, 2014) are listed under the bold dividing line

\* We have already updated the Data Book on our home page.